WE CLAIM:

1. A stable bupropion hydrochloride tablet, wherein the tablet is free of stabilizer and contains at least about 80% of undegraded bupropion hydrochloride after storage for two months at 40°C and 75% relative humidity.

2. The tablet according to claim 1, wherein the tablet is a sustained release tablet.

3. The tablet according to claim 1, wherein the tablet comprises bupropion hydrochloride, one or more release rate controlling polymers, and one or more diluents, binders, lubricants, glidants and coloring agents.

4. The tablet according to claim 3, wherein the release rate controlling polymers comprises one or more of cellulose derivatives, acrylates, polyvinlyacetate/povidone mixtures, polyethylene oxides, starches and their derivatives, gums, alginates, carbohydrate based polymers, polysaccharide, and combinations thereof.

5. The tablet according to claim 4, wherein the cellulose derivative comprises one or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and combinations thereof.

6. The tablet according to claim 5, wherein the cellulose derivative comprises hydroxypropyl cellulose.

7. The tablet according to claim 4, wherein the acrylate comprises one or more of carbomer, polycarbophil, and EUDRAGIT®.

8. The tablet according to claim 7, wherein the carbomer comprises one or more of Carbopol® -971 P, 974 P, and 934 P.

9. The tablet according to claim 3, wherein the binder comprises one or more of starch, gelatin, highly dispersed silica, mannitol, lactose, polyethylene glycol, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, cross-linked

carboxymethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose and natural, and synthetic gums.

10. The tablet according to claim 3, wherein the diluent comprises microcrystalline cellulose.

11. The tablet according to claim 3, wherein the lubricant comprises stearic acid.

12. A method of stabilizing bupropion hydrochloride tablets using a dry granulation process, the dry granulation process comprising:
a) blending bupropion hydrochloride and one or more pharmaceutically acceptable excipient(s),
b) compacting or slugging the material of step (a),
c) sizing the compacted or slugged material of step (b) into granules, and
d) compressing the granules of step (c).

13. The method according to claim 12, wherein the tablet contains at least about 80% of undegraded bupropion hydrochloride after storage for two months at 40°C and 75% relative humidity.

14. The method according to claim 12, wherein step (b) comprises compaction.

15. The method according to claim 14, wherein the compaction comprises using a roller compactor.

16. The method according to claim 12, wherein step (c) comprises milling.

17. The method according to claim 12, further comprising lubricating the sized granules of step (c) before compressing the granules.

18. The method according to claim 12, further comprising coating the tablet after compressing the granules.

19. The method according to claim 12, wherein the one or more pharmaceutically acceptable excipients comprise one or more of release rate controlling polymers, diluents, binders, lubricants, glidants, and coloring agents.

20. The method according to claim 19, wherein the release rate controlling polymers comprise one or more of cellulose derivatives, acrylates, polyvinlyacetate/povidone mixtures, polyethylene oxides, starches and their derivatives, gums, alginates, carbohydrate based polymers, polysaccharide, and combinations thereof.

21. The method according to claim 20, wherein the cellulose derivative comprises one or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and combinations thereof.

22. The method according to claim 21, wherein the cellulose derivative comprises hydroxypropyl cellulose.

23. The method according to claim 20, wherein the acrylate comprises one or more of carbomer, polycarbophil, and EUDRAGIT®.

24. The method according to claim 23, wherein carbomer comprises one or more of Carbopol® -971 P, 974 P and 934 P.

25. The method according to claim 19, wherein the binder comprises one or more of from starch, gelatin, highly dispersed silica, mannitol, lactose, polyethylene glycol, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, cross-linked carboxymethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and natural or synthetic gums.

26. The method according to claim 19, wherein the diluent comprises microcrystalline cellulose.

27. The method according to claim 19, wherein the lubricant comprises stearic acid.

28. The method according to claim 12, wherein the bupropion hydrochloride tablets are free of stabilizer.

29. A method of one or both of treating depression and providing smoking cessation, the method comprising:

providing bupropion hydrochloride in a dosage form,
wherein the dosage form is free of stabilizer and contains at least about 80% of undegraded bupropion hydrochloride after storage for two months at 40°C and 75% relative humidity.

30. The method of claim 29, wherein the dosage form is produced using a dry granulation process, the dry granulation process comprising (a) blending bupropion hydrochloride and one or more pharmaceutically acceptable excipients, (b) either compacting or slugging the blend of step (a), sizing the compacted or slugged material of step (b) into granules, and (d) compressing the granules of step (c).